About Us

Contact Us

Global Headquarters
Schering-Plough Corporation World Headquarters

2000 Galloping Hill Road
Kenilworth, N.J. 07033-0530
United States

Telephone: +1 (908) 298-4000

Directions to our New Jersey locations

Partnerships

In today's competitive pharmaceutical industry, strategic licensing agreements and partnerships are key to maintaining a balanced portfolio of products and technologies. To partner with us, please contact a representative in one of the following areas:

Human PrescriptionConsumer Health Care
Animal HealthMergers & Acquisitions


Growing Stronger, Growing Better

Read more about the combination...

Our combination with Organon BioSciences is a transformational step on Schering-Plough’s continuing journey as we build a high-performance company for the long term.



Read more about the combination...

Basic Facts & Figures

World Headquarters
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530

Chairman and CEO
Fred Hassan

Number of employees
51,000

Net sales (2008)
$18.5 billion

Business Operations in
more than 140 countries

Largest-selling products
VYTORIN*, ZETIA*, REMICADE, NASONEX, TEMODAR

R&D investment (2008)
$3.5 billion

Areas of research
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $4.5 billion in 2008.

How we work

Schering-Plough's corporate culture includes its vision, mission, Leader Behaviors and values. Our vision defines our aspirations. Our mission clarifies what success looks like and what actions will get us there. We call the core behaviors that we all must model our Leader Behaviors. And, our values are what we believe in. You can learn more about each of these below.


Action Agenda 

The Action Agenda is the six- to eight-year blueprint to transform Schering-Plough into a global, high-performance competitor for the long term. It is anchored on the principles of "new thinking, new capabilities and new urgency" -- the drivers of continuous renewal and reinvention.

Schering-Plough's Action Agenda, which was launched in 2003, is a six- to eight-year plan with five phases: Stabilize, Repair, Turnaround, Build the Base and Breakout. The first three phases are complete, and the company is now in the Build the Base phase. We are building the breadth and depth of our capabilities and extending our strength to new patients, new customers and new markets.

When the Action Agenda's fourth phase is completed, the company will enter the final part of its transformational journey. During Breakout, Schering-Plough will achieve continued superior performance and leadership in the pharmaceutical industry.